TipHub

₹1,107.2

▲ +25.42 +2.35%

As of 22 Sept 2026 · delayed

NSE Listed

ASM 1

Orchid Pharma Limited (ORCHPHARMA)

Volume: 4,93,833Avg Vol 1W: 2,63,508.2Avg Vol 1M: 1,17,848.5552W Range:₹480₹1,143.5
NSE BSE www.orchidpharma.com AI Report
Key Ratios
Checked 5h ago
Market Cap₹6,630 Cr
Current Price₹1,107.2
Previous Close₹1,081.78
High / Low (52w)₹1,143.5 / ₹480
Volume4,93,833
Avg Vol (1W)2,63,508.2
Avg Vol (1M)1,17,848.55
Stock P/E366.62
Book Value₹261.22
Dividend Yield0%
ROE134.3%
ROA62.5%
Revenue (TTM)₹1,269 Cr
Revenue Growth12.5%
Profit Margin100%
Total Debt₹132 Cr
Shares Outstanding6 Cr
Face Value₹10
EPS (TTM)₹3.02
P/B4.24
Debt / Equity0.15
50 DMA₹1,004.29
200 DMA₹796.84
Day change+2.35%
SurveillanceASM 1
Price Chart
₹1,107.2▲ 44.48% · 1Y
₹1107₹48232.6L
2025-09-22
2026-09-22

20-day avg volume: 1.2L shares

Pros
  • Healthy return on equity of 134.3%.
  • Company is almost debt-free.
  • Revenue grew 21% YoY.
Cons
  • Stock trades at a high P/E of 367.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹223 Cr₹217 Cr₹237 Cr₹263 Cr₹194 Cr₹207 Cr₹368 Cr₹304 Cr
EBITDA₹29 Cr₹26 Cr₹23 Cr₹-5 Cr₹0 Cr₹-2 Cr₹27 Cr₹5 Cr
Net Profit₹27 Cr₹21 Cr₹22 Cr₹-6 Cr₹-6 Cr₹-13 Cr₹26 Cr₹3 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹1,430 Cr₹237 Cr₹263 Cr₹194 Cr₹207 Cr₹368 Cr₹1,269 Cr₹304 Cr
EBITDA₹134 Cr₹32 Cr₹0 Cr₹6 Cr₹4 Cr₹35 Cr₹27 Cr₹14 Cr
Net Profit₹135 Cr₹28 Cr₹-2 Cr₹2 Cr₹-6 Cr₹33 Cr₹10 Cr₹12 Cr
EPS22.55—————1.66—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹3,077 Cr₹1,460 Cr₹1,237 Cr₹1,111 Cr₹1,225 Cr₹1,554 Cr₹2,077 Cr₹2,258 Cr
Total Liabilities₹3,781 Cr₹694 Cr₹584 Cr₹463 Cr₹537 Cr₹384 Cr₹523 Cr₹694 Cr
Equity₹-704 Cr₹766 Cr₹653 Cr₹647 Cr₹689 Cr₹1,169 Cr₹1,554 Cr₹1,564 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹16 Cr₹70 Cr₹19 Cr₹94 Cr₹19 Cr₹125 Cr₹67 Cr₹123 Cr
Investing₹45 Cr₹167 Cr₹67 Cr₹113 Cr₹-31 Cr₹-312 Cr₹-36 Cr₹-277 Cr
Financing₹0 Cr₹-250 Cr₹-165 Cr₹-217 Cr₹31 Cr₹167 Cr₹2 Cr₹137 Cr
Free Cash Flow₹16 Cr₹70 Cr₹19 Cr₹94 Cr₹19 Cr₹125 Cr₹67 Cr₹123 Cr
Shareholding
Promoter 69.84% Institutions 21.55% Public 8.61%
Efficiency & Working Capital
ROCE1.6%
Interest Coverage3.5
Dividend Payout—
Debtor Days113 d
Inventory Days110 d
Payable Days103 d
Cash Conversion Cycle120 d
Working Capital Days223 d
Shareholding Details

As of 2026-06-30

Promoter69.8%
FII0.8%
DII20.7%
Institutions21.6%
Public8.6%
Promoter Pledge0%
No. of Shareholders33,433
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters72.4%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%
FIIs8.1%4.1%2%1.4%1.9%2.5%2.7%1.4%1.6%1.2%0.9%0.8%
DIIs9.9%14.5%17.7%18.9%18.3%19%20.1%19.4%19%19.4%20.2%20.7%
Public9.6%11.5%10.5%9.8%9.9%8.6%7.4%9.3%9.6%9.6%9%8.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders29,19736,93136,72034,69536,36334,15834,30339,82738,15535,70935,11833,433
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Dhanuka Laboratories LimitedShareholding of Promoter and Promoter Group69.8%3.54 Cr
Quant Mutual Fund - Quant Small Cap FundPublic Shareholding6.8%34,65,947
Kotak Mahindra Trustee Co Ltd A/c Kotak Consumption Fund And 7 OthersPublic Shareholding4.6%23,35,445
Uti Small Cap Fund And 3 OthersPublic Shareholding3.5%17,55,037
Invesco India Contra Fund And 2 OthersPublic Shareholding2.9%14,56,510
Bandhan Small Cap Fund And 5 OthersPublic Shareholding1.5%7,76,976
Mimi AgarwallaPublic Shareholding0%2,396
Board of Directors
NameDesignationYear
R G AgarwalChairman(Non Exe)&Dir(Non-Ind)2025
Manish DhanukaExecutive Director & MD2025
Mridul DhanukaE D & Wholetime Director2025
Arjun DhanukaNon-Exec & Non-Independent Dir2025
Dharam VirIndependent Non Exe. Director2025
Manoj GoyalIndependent Non Exe. Director2025
Tanu SinglaIndependent Non Exe. Director2025
Shubha SinghIndependent Non Exe. Director2025
Kapil DayyaCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹415 Cr34.3%
Rest of the world₹796 Cr65.7%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹101656015
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-14Board Meetings—
forthcoming2026-08-01Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025558008233—
20255660000566
2025-130000-13
Insider / Designated-Person Trades

3 recent disclosure(s)

DHANUKA LABORATORIES LIMITEDDisposal · 13,00,000
Dhanuka Laboratories LimitedRevoke · 80,00,015
Dhanuka Laboratories LimitedRevoke · 1,20,00,022
Substantial Acquisitions (SAST)

6 disclosure(s)

Market26/12/2023 · 15,385
Market22/12/2023 · 69,782
Invocation19/12/2023 · 85,167
Market11/12/2023 - 15/12/2023 · 10,00,000
Off Market28/11/2023 · 13,00,000
Release of Shares19/01/2022 · —
Company Information
Incorporated1992
ChairmanR G Agarwal
AuditorSinghi & Co
Investor Email[email protected]
🌐 www.orchidpharma.com ↗

📍 Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road, Chennai, Tamil Nadu, 600034

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Optiemus Infracom Ltd.Optimus Finance Ltd.Optimystix Entertainment India Ltd.Optivalue Tek Consulting Ltd.Orbit Exports LimitedOrchasp LimitedOriana Power LimitedOricon Enterprises Ltd.Oriental Trimex Ltd.Orient Bell LimitedOrient Cement Ltd.Orient Ceratech LimitedAll “O” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search